Amgen clotting drug gets FDA nod

Now it's time for the press release: The FDA approved Amgen's Nplate drug to treat a rare blood-clotting disorder that causes the body to attack its own platelets. Last month, Amgen mistakenly announced that Nplate had won the FDA nod, and had to retract the press release. This time, though, it's for real. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.